Literature DB >> 11525811

Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells.

E Wiesemann1, J Klatt, D Sönmez, R Blasczyk, F Heidenreich, A Windhagen.   

Abstract

In order to define possible mechanisms of immunomodulation by glatiramer acetate (GA), we investigated the primary in vitro cytokine response of peripheral blood mononuclear cells (PBMCs) and T-cell subpopulations. In PBMCs from healthy subjects and untreated patients with multiple sclerosis (MS) GA-induced T-cell proliferation and mRNA expression/cytokine, secretion of IL-13 and IL-5 but not of IL-10, TGF-beta or IL-12, IL-4 was detected at the mRNA level only. IFN-gamma was induced in a few subjects at very low concentrations. The response to GA was driven by the CD4(+)/CD45RA(+) T-cell subpopulation and was mediated by T-cell receptor (TCR) engagement as determined by anti-TCR blocking antibodies. The findings are compatible with the hypothesis that GA functions as partial or weak TCR-agonist activating naive T cells to produce the Th2 cytokines IL-13 and IL-5.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11525811     DOI: 10.1016/s0165-5728(01)00379-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

1.  Glatiramer acetate modulates TNF-α and IL-10 secretion in microglia and promotes their phagocytic activity.

Authors:  Refik Pul; Darius Moharregh-Khiabani; Jelena Škuljec; Thomas Skripuletz; Niklas Garde; Elke Verena Voss; Martin Stangel
Journal:  J Neuroimmune Pharmacol       Date:  2010-11-03       Impact factor: 4.147

2.  Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis.

Authors:  A Sanna; M L Fois; G Arru; Y-M Huang; H Link; M Pugliatti; G Rosati; S Sotgiu
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

Review 3.  Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

Authors:  Patrice H Lalive; Oliver Neuhaus; Mahdia Benkhoucha; Danielle Burger; Reinhard Hohlfeld; Scott S Zamvil; Martin S Weber
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

4.  Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis.

Authors:  E Wiesemann; J Klatt; C Wenzel; F Heidenreich; A Windhagen
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

Review 5.  Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.

Authors:  Martin S Weber; Reinhard Hohlfeld; Scott S Zamvil
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

6.  T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis.

Authors:  Chris J Hedegaard; Martin Krakauer; Klaus Bendtzen; Henrik Lund; Finn Sellebjerg; Claus H Nielsen
Journal:  Immunology       Date:  2008-04-04       Impact factor: 7.397

7.  T cell immunity to glatiramer acetate ameliorates cognitive deficits induced by chronic cerebral hypoperfusion by modulating the microenvironment.

Authors:  Li Chen; Yang Yao; Changjuan Wei; Yanan Sun; Xiaofeng Ma; Rongxin Zhang; Xiaolin Xu; Junwei Hao
Journal:  Sci Rep       Date:  2015-09-22       Impact factor: 4.379

8.  A Single Nucleotide ADA Genetic Variant Is Associated to Central Inflammation and Clinical Presentation in MS: Implications for Cladribine Treatment.

Authors:  Mario Stampanoni Bassi; Fabio Buttari; Ilaria Simonelli; Luana Gilio; Roberto Furlan; Annamaria Finardi; Girolama Alessandra Marfia; Andrea Visconti; Andrea Paolillo; Marianna Storto; Stefano Gambardella; Rosangela Ferese; Marco Salvetti; Antonio Uccelli; Giuseppe Matarese; Diego Centonze; Francesca De Vito
Journal:  Genes (Basel)       Date:  2020-09-30       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.